: iStockAnalyst.com Symbols Feed

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Wed, 07 Oct 2009 19:22:50 GMT

The procedure has been called "one of the most barbaric mistakes ever perpetrated by mainstream medicine." Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.[More...]

Late Bounce Leaves Stocks Near Steady

Tue, 09 Jun 2009 00:11:05 GMT

Stocks clawed back in afternoon trading to finish narrowly mixed. The Dow Jones Industrial Average is up 1 point or 0.01%, while the S&P 500 is down 1 point or 0.1%. The Nasdaq Composite ends in the middle of the day's range, down 7 points or 0.4%.[More...]

These Shady Biotechs Are Duping You

Fri, 22 May 2009 13:47:00 GMT

Stem cells are a biologic marvel and a political football. Because stem cells never die and they have the ability to evolve into nearly all cell types, they are the leading source of groundbreaking medical advances. For example, researchers hope to transform stem cells into heart cells, which could be injected into heart-attack patients to repair the damage. In the lab, scientists have pulled off virtual miracles with stem cells. Rats with crushed spinal cords are able to walk again after growing new neurons. Mice with diabetes grow new pancreas cells that secrete insulin. Such results have spurred hope in patients with debilitating diseases. Famously, Christopher Reeves, the actor who played Superman, believed stem cells could cure his spinal cord injury, perhaps allowing him to walk again. He died before he got his chance... And we are still at least a[More...]

Stem Cell Research Reversal Sends Biotech Stocks Up

Mon, 09 Mar 2009 17:54:00 GMT

Whether you’re happy about the latest development from Washington depends on what side of the political aisle you normally sit on, but President Obama’s latest executive decision is causing a stir one way or the other since it involved the controversial usage of embryonic stem cell research. Flashback the length of two presidential terms to the first year of the Bush administration. Prior to that time, federal funding was allowed by law to go towards funding research done with human embryonic stem cells. But in August 2001, then president Bush reversed the decision based on ethical grounds and the conviction that human life started at the moment of conception. Though researchers could still receive funding for already-existing batches of the cells contained within the days-old human embryos, they unsurprisingly weren’t happy with the removal of further financial support. That’s all changed with a reversal of the[More...]

Global Stem Cell and Regenerative Medicine Index

Wed, 18 Feb 2009 00:55:00 GMT

The accompanying table (click to enlarge) includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously. The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close[More...]

Beyond Stem Cells: Healthcare Hot Spots

Mon, 26 Jan 2009 18:09:00 GMT

With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM). Below are three additional areas and associated companies for investors to consider in the search of the next hot spots in the healthcare sector, including a focus on small/mid-cap companies which have the added potential to be acquired as part of renewed M&A in the sector this year. Molecular Diagnostics EXACT Sciences (EXAS) has rejected the hostile $1.50 all-stock offer from[More...]

Index to Track New Era for Stem Cell Cos.

Fri, 23 Jan 2009 16:12:00 GMT

Shares of Geron (GERN) are soaring today by more than 40% on FDA approval to begin human clinical testing this summer for an embryonic stem cell treatment for spinal cord injuries. The approval comes just days after the new administration took office, breathing new life into related companies such as StemCells (STEM), Aastrom Biosciences (ASTM), and others tracked in the ETF Innovators Cosmetic & Reconstructive Medicine Index. This index and new ETF idea represents a[More...]

Stem Cell & Regenerative Medicine Stocks Surge in Past Month

Sat, 20 Dec 2008 00:03:00 GMT

The accompanying table (click to enlarge) includes the Top 10 Rated companies among a total of 64 and statistics for the ETF Innovators (ETFI) Cosmetic and Reconstructive Medicine (CRM) Index, which includes companies with market caps over $100M engaged in cosmetic medicine products, regenerative medicine + stem cells, orthopedic repair, joint replacements, and cardiovascular (heart + blood vessels) treatments. The Top 10 Rated companies are dominated by those focusing on cardiovascular[More...]

StemCells, Inc. Announces FDA Approval to Initiate Clinical Trial of HuCNS-SC(R) Cells in a Myelin Disease

Fri, 19 Dec 2008 19:20:00 GMT

StemCells, Inc. announced this morning that it has received approval from the FDA to begin a clinical trial of the Company’s proprietary HuCNS-SC product candidate (purified human neural stem cells) to treat Pelizaeus-Merzbacher Disease (PMD), a fatal brain disorder that primarily affects young children. As of today, there are no approved treatments for this disease. According to the press release, this is the Company’s second FDA-approved clinical trial to evaluate HuCNS-SC cells as a potential treatment for neurodegenerative diseases. The first study to be approved was the Company’s Phase I clinical trial of HuCNS-SC cells to treat neuronal ceroid lipofuscinoses (NCL), or Batten disease. The Phase I NCL trial is predicted to reach completion next month. “PMD is one of the most severe myelin disorders known to man. Children afflicted with this disease suffer progressive neurodegeneration and an untimely death. Unfortunately, they have[More...]

Healthcare Investing Trends for 2009

Thu, 18 Dec 2008 14:37:00 GMT

Healthcare investing trends in 2009 and beyond will be affected by the new administration's plans for healthcare reform, which are summarized at the Change.gov website. A key feature of the plan is making health insurance coverage possible for all Americans using the existing network of insurers and providers. The plan relies on tax credits for small businesses and eligible individuals to help pay the cost of health insurance premiums. Also, large employers which do not offer health insurance benefits would be required to contribute a percentage of their payroll toward the cost of healthcare for their employees. Insurance companies would be required to cover pre-existing conditions and the insurance market will be reformed to eliminate anti-competitive practices, including the creation of a National Health Insurance Exchange with a variety of affordable health insurance options.[More...]

Dallas-Fort Worth School Districts Calculate Different Ways to Use Netbooks in Classes

Mon, 21 Sep 2009 07:49:00 GMT

The small computers are much lighter and cheaper than traditional laptop computers.
One sign of that shift took place when the Irving school district decided in May to begin replacing aging and bulkier student laptops with about 4,600 netbooks.
"It's a lot easier to carry," said Luis Hernandez, 11, a Travis Middle School student.

: iStockAnalyst.com Symbols Feed

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Late Bounce Leaves Stocks Near Steady

These Shady Biotechs Are Duping You

Stem Cell Research Reversal Sends Biotech Stocks Up

Global Stem Cell and Regenerative Medicine Index

Beyond Stem Cells: Healthcare Hot Spots

Index to Track New Era for Stem Cell Cos.

Stem Cell & Regenerative Medicine Stocks Surge in Past Month

StemCells, Inc. Announces FDA Approval to Initiate Clinical Trial of HuCNS-SC(R) Cells in a Myelin Disease

Healthcare Investing Trends for 2009

Dallas-Fort Worth School Districts Calculate Different Ways to Use Netbooks in Classes

CIS, Wyeth Donate Laptop to ELMS Student

StemCells to Acquire Assets of Stem Cell Sciences

StemCells Comments on PLoS Medicine Article

Jobless Rate at 15-Year High: Unemployment Increases in Area, but Still Lower Than State

SmallCapSentinel.com: Bone Marrow Stem Cell Company Profile Released

StockPreacher.com Issues Trading Outlook for Advanced Cell Technology Inc.

StemCells, Inc. Reports Second Quarter Financial Results

InvestorSoup.Com Issues Investment Report for Geron Corp.

StemCells, Inc. to be Added to Russell 3000 Index

StemCells, Inc. to Present at Jefferies Third Annual Healthcare Conference

StemCells, Inc. Announces Positive Phase I Batten Trial Results

StemCells, Inc. to Present Phase I Clinical Trial Results at the 12th International Congress on NCL

U.S. Patent Office Upholds StemCells' Patents -- Company Moves to Resume Patent Infringement Cases Against Neuralstem

U.S. Patent Office Upholds StemCells’ Patents – Company Moves to Resume Patent Infringement Cases Against Neuralstem

Form 4 WEISSMAN IRVING For: Oct 01 (10K)

Form 4 TSUKAMOTO ANN For: Aug 17 (10K)

Form 4 TSUKAMOTO ANN For: May 15 (10K)

Form 4 SCHWARTZ JOHN J For: Apr 17 (10K)

Form 4 WEISSMAN IRVING For: Apr 16 (10K)

Form 4/A KOSHY GEORGE For: Apr 02 (10K)

Form 4 KOSHY GEORGE For: Apr 07 (10K)

Form 4 CRAIG STEWART For: Sep 15 (10K)

Form 3 CRAIG STEWART For: Sep 15 (10K)

Form 4 Stratton Kenneth Blair For: Mar 10 (10K)